Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Who's Buying Now?

It's a new week, which means it's time to check the most interesting insider purchases. After reading through numerous filings using insider tracking tool Form 4 Oracle, here are my top five from the past seven days.

The week's buying


Closing Price 7/25/06

Total Value of Stock Purchased

52-Week Change

Fastenal (Nasdaq: FAST  )




Luby's (NYSE: LUB  )




Methode Electronics (Nasdaq: METH  )




St. Jude Medical (NYSE: STJ  )




TD Ameritrade (Nasdaq: AMTD  )




Sources:, Yahoo! Finance, Form 4 Oracle, SEC filings

In praise of METH
Last September, when fellow Fool Shannon Zimmerman examined Methode Electronics, rising oil prices had recently punished the bottom line. Nevertheless, the company remained optimistic, projecting full-year sales of $385 million and per-share earnings of $0.56 to $0.63.

Fast forward to mid-July. Full-year results are in, and despite $421.6 million in sales -- well ahead of earlier estimates -- the bottom line didn't measure up, managing only $0.47 of net income. To its credit, Methode didn't blame its miss on a sneezing rhino on the African plain or a poor economic climate. Instead, it cited internal inefficiencies, its cost of doing business in China, and trouble at its automotive customers. Investors didn't seem to care, though; the shares are down 16% since the earnings news.

For management, that's created a buying opportunity. Methode insiders have been loading up on shares since last Wednesday, led by board member Christopher Hornung, who purchased 10,000 shares. CEO Donald Duda, Chief Financial Officer Douglas Koman, and board member Paul Shelton also participated in the buying spree.

Is there merit to the purchases? Well, the stock does look cheap. According to Yahoo! Finance, Methode trades for roughly 1.2 times its tangible book value and 15 times forward earnings. That leaves a lot of room for upside, especially if management can find a way to begin meeting the Street's lowered expectations. Keep an eye on this one, Fool.

Is Luby's worth the label?
Next up is restaurateur Luby's, which operates 131 locations around the American South and Southwest. More could be in the works. Third-quarter earnings were impressive; net profit rose roughly 19% year over year, after adjusting for a one-time tax gain. In addition, the chain has managed to increase same-store sales for 10 consecutive quarters, including a 4% bump in Q3.

Against that backdrop, management is buying. Last Wednesday, Chief Financial Officer Ernest Pekmezaris spent $54,000 to snap up 6,000 shares, boosting his direct holdings by more than 20%. That's encouraging, and it continues a trend: Insiders own more than 26% of Luby's available shares.

Meanwhile, institutions have yet to buy into the Luby's story, owning roughly 40% of the float. But the funds that have taken a nibble are some of the best in the business, including the five-star Bridgeway Ultra-Small Company Market (FUND: BRSIX  ) , which has pummeled the S&P 500 over the past five years. It's also a cousin to Bridgeway Small Cap Value (FUND: BRSVX  ) , which has been a stellar performer for the Motley Fool Champion Funds portfolio. Color me intrigued.

And that's all for this week. See you back here next Wednesday, when we dig through more insider deals in search of the next home run stock.

Get the inside scoop on stocks of all sizes with this related Foolishness:

Get all of the inside information you need in our collection ofinvesting newsletters. From wallflowerish small caps to swashbuckling Rule Breakers we've got something for every investor.Get in on the actiontoday; all of our newsletters offer a 30-day risk-free trial. All you have to lose is the prospect of better returns.

Fool contributorTim Beyersusually favors two scoops of ice cream over the inside scoop. Tim didn't own shares in any of the companies mentioned in this story at the time of publication. You can find out what is in his portfolio by checking Tim's Foolprofile. The Motley Fool has an ironcladdisclosure policy.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 506314, ~/Articles/ArticleHandler.aspx, 10/23/2016 10:55:15 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
AMTD $37.08 Up +0.44 +1.20%
TD Ameritrade CAPS Rating: *****
BRSIX $14.12 Down -0.04 -0.28%
BRSVX $21.48 Down -0.08 -0.37%
FAST $38.37 Down -0.14 -0.36%
Fastenal CAPS Rating: ****
LUB $4.31 Up +0.18 +4.36%
Luby's CAPS Rating: *****
STJ $79.36 Down -0.27 -0.34%
St. Jude Medical CAPS Rating: **